Apnimed

Apnimed is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing novel oral therapies for sleep-related breathing diseases. The company's vision is to simplify treatment and improve oxygenation for people living with obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. Its most advanced candidate, AD109, is designed as a convenient oral alternative to current standard-of-care treatments like CPAP machines.